We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Allergan Denies Delaying Restasis Generic In Bid To Stop MDL

Law360 (June 20, 2018, 7:12 PM EDT) -- Allergan Inc. asked a New York federal court to throw out multidistrict litigation over its alleged effort to delay the launch of a generic version of Restasis, the company’s dry-eye medication, saying there’s no evidence its actions caused a generic not to be approved.

Allergan on Tuesday filed reply briefs supporting its efforts to dismiss allegations over its Restasis-related conduct, which includes transferring the patents to a Native American tribe. The company said several months ago that its patents for the dry-eye drug were invalidated, but...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.